Xeljanz XR (tofacitinib)

pCPA File Number: 21096
Negotiation Status:
Concluded with an LOI
Indication(s):
Subacute and chronic inflammatory joint diseases
Sponsor/Manufacturer:
Pfizer Canada ULC
CADTH Project Number:
Not Applicable
pCPA Engagement Letter Issued:
Negotiation Process Concluded: